Determination of JW5473 in Rat Plasma by UPLC-MS/MS and its Application to Pharmacokinetic Study of JW5473

Abstract

A sensitive method for quantitation of JW5473 in rat plasma has been established using ultra performance liquid chromatography-electrospray ionization tandem mass spectrometry (UPLC-ESI/MS/MS). Tramadol was used as an internal standard. JW5473 and internal standard in plasma sample was extracted using acetonitrile (protein precipitation). A centrifuged upper layer was then evaporated and reconstituted with the mobile phase of 0.5% formic acid-acetonitrile (40:60, v/v). The reconstituted samples were injected into a C₁₈ reversed-phase column. Using MS/MS in the multiple reaction monitoring (MRM) mode, JW5473 and tramadol were detected without severe interference from rat plasma matrix. JW5473 produced a protonated precursor ion ([M+H]⁺) at m/z 432.3 and a corresponding product ion at m/z 114.4. And the internal standard produced a protonated precursor ion ([M+H]⁺) at m/z 264.4 and a corresponding product ion at m/z 58.1. Detection of JW5473 in human plasma by the UPLC-ESI/MS/MS method was accurate and precise with a quantitation limit of 1.0 ng/mL. The validation, reproducibility, stability, and recovery of the method were evaluated. The method has been successfully applied to pharmacokinetic studies of JW5473 in rat plasma. Pharmacokinetic parameters of JW5473 was evaluated after intravenous (i. v.; at doses of 15 mg/kg) and oral (p.o.; at doses of 30 mg/kg) administration of JW5473 in rats. After p.o. administration (30 mg/kg) of JW5473, F (Fraction absorbed) value was approximately 70.5%.

Key words

JW5473 - tramadol - UPLC-ESI/MS/MS - bioavailability - rats

• References

• 1 Rosamond W, Flegal K, Furie K. et al. Heart disease and stroke statistics: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008; 117: 25-146
• 2 Grundy SM, Cleeman JI, Merz CN. et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-239
• 3 Fernandez G, Spatz ES, Jablecki C. et al. Statin myopathy: A common dilemma not reflected in clinical trials. Cleveland Clinic Journal of Medicine 2011; 78: 393-403
• 4 Saurav A, Kaushik M, Mohiuddin SM. Fenofibric acid for hyperlipidemia. Expert Opinion on Pharmacotherapy 2012; 13: 717-722
• 5 Staels B, Dallongeville J, Auwerx J. et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998; 98: 2088-2093
• 6 Adkins JC, Faulds D. Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia. Drugs 1997; 54: 615-633
• 7 Vogt M, Kunath K, Dressman JB. Dissolution enhancement of fenofibrate by micronization, cogrinding and spray-drying: comparison with commercial preparations. European Journal of Pharmaceutics and Biopharmaceutics 2008; 68: 283-288
• 8 Masnatta LD, Cuniberti LA, Rey RH. et al. Determination of bezafibrate, ciprofibrate and fenofibric acid in human plasma by high-performance liquid chromatography. Biomedical Chromatography 2009; 23: 922-928.
• 9 http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation /Guidances/ucm070107.pdf.
• 10 King R, Bonfiglio R, Fernandez-Metzler C. et al. Mechanistic investigation of ionization suppression in electrospray ionization. Amer. Soc. Mass. Spectrom 2000; 11: 942-950
• 11 Henion J, Brewer E, Rule G. Sample preparation for LC/MS/MS: Analyzing biological and environmental samples. Anal. Chem. 1998; 70: 650A-656A
• 12 Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharmaceutical Research 1993; 10: 1009-1095
• 13 Chiou WL. Critical evaluation of potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma level–time curve. Journal of Pharmacokinetics and Biopharmaceutics 1978; 6: 539-546